Cedars Sinai Medical Center

Los Angeles, CA, United States

Cedars Sinai Medical Center

Los Angeles, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Cedars Sinai Medical Center | Date: 2017-04-12

Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH + MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.


Patent
Cedars Sinai Medical Center | Date: 2017-07-12

The invention provides methods for treating fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs) in a subject in need thereof. The methods include providing a composition comprising a Lyn inhibitor and administering an effective amount of the composition to the subject to treat fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs). fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs).


The present invention relates to methods of predicting the risk for colectomy in a subject with mrUC, by determining the presence or absence of one or more mrUC risk variants. Other embodiment, relate to methods of treating mrUC in a subject and a kit for prognostic use.


Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non- covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence


Patent
Cedars Sinai Medical Center and University of Michigan | Date: 2017-05-17

Described herein are kits and methods for identifying the likelihood of having a food sensitivity or intolerance, and determining dietary modifications accordingly. For example, the likelihood of having sensitivities, intolerances or allergies to gluten, lactose, FODMAPs and others tested and calculated. Additionally, diet modifications can be determined according to the likelihood of particular sensitivities, and the effectiveness of diet modifications can be evaluated by monitoring of meals and subsequent symptoms, and evaluating the monitoring information. Through application of the methods herein, dietary intake and symptom data may be collected and aggregated to evaluate the effect or desirability of particular foods on a population of interest.


Patent
Cedars Sinai Medical Center | Date: 2017-01-04

Some embodiments of the invention include a device for creating a sterile environment when using an o-shaped or a c-shaped multidimensional surgical imaging system. The device may comprise a drape configured to drape over a patient, a cover removably attached to the drape, and an adhesive seam configured to pull apart to disassemble the drape after. The drape may have a puncture configured to engage with a spine reference clamp, a reference frame, each of the puncture and the reference frame positioned along a center line of the drape, and the cover may be removably attached to the drape to cover the puncture and the reference frame.


Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.


Patent
Cedars Sinai Medical Center | Date: 2017-06-14

This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.


Patent
Cedars Sinai Medical Center | Date: 2017-03-02

Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).


Patent
Cedars Sinai Medical Center | Date: 2017-04-19

The invention describes compounds that inhibit both HDAC and GSK3 (i.e., HDAC/GSK3 dual inhibitors). The invention further describes compositions containing these HDAC/GSK3 dual inhibitors, as well as methods and kits using these HDAC/GSK3 dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3 to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3. Medical conditions treatable with various embodiments of the invention include but are not limited to caners and tumors.

Loading Cedars Sinai Medical Center collaborators
Loading Cedars Sinai Medical Center collaborators